Boosted Reyataz comparable to Kaletra.
D000069446:Atazanavir Sulfate; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir; D008297:Male; D020714:Maximum Tolerated Dose; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D011336:Probability; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D061466:Lopinavir; D000069446:Atazanavir Sulfate